Table 1.
Sociodemographic data and disease properties of patients with IBD
| All patients with IBD (n=177) |
Group A
|
Group B
|
|
|---|---|---|---|
| (n=47) | (n=20) | ||
| Age (years), mean ± SD | 40.71±12.71 | 39.06±11.67 | 41.65±13.90 |
| Female sex n (%) | 99 (55.9) | 36 (76.6) | 7 (35.0) |
| UC, n (%) | 98 (55.4) | 24 (51.1) | 12 (60.0) |
| CD, n (%) | 79 (44.6) | 23 (48.9) | 8 (40.0) |
| Montreal classification | |||
| Age at diagnosis of CD, n (%) | |||
| A2 17 <40 years | 64 (81.0) | 19 (82.6) | 5 (62.5) |
| A3 ≥40 years | 15 (19.0) | 4 (17.4) | 3 (37.5) |
| Localization of CD, n (%) | |||
| L1 ileal | 37 (46.8) | 13 (56.6) | 3 (37.5) |
| L2 colonic | 8 (10.1) | 1 (4.3) | 0 (0.0) |
| L3 ileocolonic | 33 (41.8) | 8 (34.8) | 5 (62.5) |
| L4 isolated upper disease | 1 (1.3) | 1 (4.3) | 0 (0.0) |
| Behavior of CD, n (%) | |||
| B1 nonstructuring, nonpenetrating | 47 (59.5) | 16 (69.6) | 5 (62.5) |
| B2 structuring | 9 (11.4) | 1 (4.3) | 1 (12.5) |
| B3 penetrating | 23 (29.1) | 6 (26.1) | 2 (25.0) |
| p perianal disease modifier | 16 (9.0) | 7 (14.9) | 5 (25.0) |
| Extent of UC, n (%) | |||
| E1 ulcerative proctitis | 33 (33.7) | 4 (16.7) | 4 (33.3) |
| E2 left-sided UC (distal UC) | 33 (33.7) | 9 (37.5) | 4 (33.3) |
| E3 extensive UC (pancolitis) | 32 (32.6) | 11 (45.8) | 4 (33.3) |
| Smoking | 39 (22.0) | 10 (21.2) | 8 (40.0) |
| Alcohol consumption | 9 (5.0) | 2 (4.2) | 3 (15.0) |
| Drug usage, n (%) | |||
| Anti-TNF | 56 (31.6) | 21 (44.7) | 4 (20.0) |
| Corticosteroids | 14 (7.9) | 3 (6.4) | 1 (5.0) |
| Azathioprin | 80 (45.2) | 22 (46.8) | 7 (35.0) |
| Methotrexate | 4 (2.3) | 7 (14.9) | 1 (5.0) |
| Mesalamine | 113 (63.8) | 31 (66.0) | 14 (70.0) |
| Budesonide | 4 (2.3) | 1 (2.1) | 2 (10.0) |
| IBD severity at baseline visit,a n (%) | |||
| Inactive | 105 (59.3) | 26 (55.3) | 8 (40.0) |
| Mildly active | 53 (29.9) | 14 (29.8) | 9 (45.0) |
| Moderately active | 19 (10.8) | 7 (14.9) | 3 (15.0) |
| Past psychiatric treatment history | 37 (20.9) | 12 (25.5) | 4 (20.0) |
| Family history of a psychiatric disease | 18 (10.2) | 8 (17.0) | 3 (15.0) |
| Sleep disturbance symptoms | 80 (45.2) | 35 (74.5) | 12 (60.0) |
Notes:
a
Disease severity indexes: CDAI =0–150 (inactive), 150–300 (moderate), >300 (severe), modified Mayo =0–1 (inactive), 2–5 (moderate), >5 (severe). Group A: patients maintained psychiatric drug therapy during 6 months; Group B: patients could not maintain psychiatric drug therapy of 6 months.
Abbreviations: CD, Crohn’s disease; CDAI, Crohn’s disease activity index; IBD, inflammatory bowel disease; TNF, tumor necrosis factor; UC, ulcerative colitis.